Trial reportJournal of endocrinological investigation2006
Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.
Trial report in Journal of endocrinological investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Immunomodulators in Graves' ophthalmopathy: a systematic review.Frontiers in endocrinology · 2026Pooled it
- Randomized controlled trial of rituximab in patients with Graves' orbitopathy.The Journal of clinical endocrinology and metabolism · 2015Trial
- Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.International journal of molecular sciences · 2026Review
- Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.Frontiers in endocrinology · 2024Review
- Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.European thyroid journal · 2020Article
- Thyroid eye disease: current and potential medical management.International ophthalmology · 2020Review
- Review
- Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.Therapeutics and clinical risk management · 2019Review
- Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis.Journal of ophthalmology · 2018Review
- The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.European thyroid journal · 2016Article
- Graves' orbitopathy: imperfect treatments for a rare disease.European thyroid journal · 2013Review
- Thyroid eye disease: towards an evidence base for treatment in the 21st century.Current neurology and neuroscience reports · 2012Review
- The evaluation and treatment of graves ophthalmopathy.The Medical clinics of North America · 2012Review
- Medical management of thyroid eye disease.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society · 2011Article
- Graves orbitopathy: a perspective.Nature reviews. Endocrinology · 2009Review
- Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy.Current opinion in endocrinology, diabetes, and obesity · 2008Review
- The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease.Clinical ophthalmology (Auckland, N.Z.) · 2007Article
- Currently available somatostatin analogs are not good for Graves' orbitopathy.Journal of endocrinological investigation · 2006Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SS analogs are an attractive alternative in treating Graves' ophthalmopathy (GO). Most of the previous studies were uncontrolled and enrolled few patients. The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO. Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks. They were then followed and further treated in the traditional way if necessary. The Clinical Activity Score (CAS) was the primary efficacy criterion. Proptosis, diplopia, corneal erosion or ulcer, visual acuity, extraocular muscle movement and intraocular pressure were also evaluated. At the end of the 12 weeks, the mean CAS was not significantly decreased in the lanreotide group compared to the placebo group. The overall mean difference of proptosis between these two groups also did not reach significance at 12 weeks. Only diplopia at downward gaze had significant improvement for the lanreotide- treated group vs placebo group (p = 0.03). No differences were observed between the two groups compared to other outcome measures. During the 24-month follow-up after the clinical trial, 14 patients received eye surgery in the placebo group compared with 10 patients in the lanreotide group (p = 0.29). Six patients received methylprednisolone pulse therapy in the placebo group and two patients in the lanreotide group (p = 0.25). In conclusion, lanreotide treatment had no significant effects on GO compared with placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.